FDA article from 28th Feb. there's some interesting takeaways here especially around the safety issues of each of these 3 approved drugs.
https://www.fda.gov/drugs/news-events-human-drugs/cder-continues-advance-rare-disease-drug-development-new-efforts-including-accelerating-rare-disease
A couple of the links to recent drug approval for rare disease does note some similarities to Trofinetide albeit their AE's appear to be much more severe than NNZ-2566
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-prurigo-nodularis
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-acid-sphingomyelinase-deficiency-rare-genetic-disease
- Forums
- ASX - By Stock
- NEU
- Ann: Rett Syndrome NDA accepted for Priority Review by FDA
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-160
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.78 |
Change
-1.360(6.14%) |
Mkt cap ! $2.656B |
Open | High | Low | Value | Volume |
$22.06 | $22.11 | $20.63 | $8.616M | 407.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 593 | $20.77 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.78 | 10 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1065 | 20.730 |
2 | 4549 | 20.670 |
3 | 2504 | 20.660 |
1 | 300 | 20.650 |
2 | 485 | 20.640 |
Price($) | Vol. | No. |
---|---|---|
20.940 | 996 | 1 |
20.950 | 1065 | 2 |
21.000 | 1028 | 2 |
21.060 | 996 | 1 |
21.120 | 996 | 1 |
Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |